Market research
DYAI Dyadic International Inc
NASDAQ USD Healthcare
Latest close
As of 30 Oct 2026
Test a moving-average rule with historical data.
Market facts
- Market cap
- 16M
- P/E ratio
- Not available
- Analyst target
- 5.5
- Dividend yield
- Not available
- Beta
- 0.96
Profile
Instrument facts
- Exchange
- NASDAQ
- Currency
- USD
- Sector
- Healthcare
- Industry
- Biotechnology
- ISIN
- Not available
- Market cap
- 16M
- P/E ratio
- Not available
- Analyst target
- 5.5
- Dividend yield
- Not available
- Beta
- 0.96
About
About Dyadic International Inc
Dyadic International, Inc., together with its subsidiaries, a biotechnology platform company, develops, manufactures, and commercializes proteins and enzymes in the United States. The company offers Dapibus Protein Production Platform, a proprietary expression system designed to produce non-animal proteins and enzymes for non-pharmaceutical markets, including life sciences, food and nutrition, and bio-industrial sector; and C1 Protein Production Platform, a thermophilic fungal platform for large-scale production of proteins. It has a research and development agreement with VTT Technical Research Centre of Finland, Ltd; license agreement with Rubic One Health to develop various livestock vaccines; sub-license agreement with Phibro Animal Health/Abic Biological Laboratories to develop vaccines and treatments for livestock diseases; and collaboration with Scripps Research to evaluate monoclonal antibody and vaccine candidates targeting hantaviruses. Dyadic International, Inc. was founded in 1979 and is headquartered in Jupiter, Florida.
Research context
Dyadic International Inc appears in PyInvesting’s US Stock catalogue. The price history above describes this recorded instrument; it does not by itself identify a company’s business or establish a continuous investment return.
- Currency
- USD
- Sector
- Healthcare
- Industry
- Biotechnology
These are the latest stored catalogue classifications, not a historical classification snapshot. An issuer description, classification effective date or currency may be unavailable. Check the issuer’s own disclosures and the observation dates before using these fields for research.
Review backtest assumptions and evidence before treating a chart or stored history as a research result.
Community
Investor discussion
1 comment
Sign in to join the DYAI discussion.
5 years, 6 months ago
Dyadic International, Inc is currently in a long term downtrend where the price is trading 33.8% below its 200 day moving average.
From a valuation standpoint, the stock is 92.9% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 94.5.
Dyadic International, Inc's total revenue sank by 20.1% to $346K since the same quarter in the previous year.
Its net income has increased by 99.9% to $-2K since the same quarter in the previous year.
Finally, its free cash flow grew by 8.1% to $-1M since the same quarter in the previous year.
Based on the above factors, Dyadic International, Inc gets an overall score of 3/5.